44 results
424B3
BIAF
BioAffinity Technologies Inc
22 May 24
Prospectus supplement
4:00pm
service fees1
Histology service fees
Medical director fees
Department of Defense observational studies
Other revenues2
Total net revenue
Patient … services provided to Village Oaks related to the Company’s CyPath® Lung test, and (3) CyPath® Lung tests purchased by the U.S. Department of Defense (“DOD
424B3
BIAF
BioAffinity Technologies Inc
22 May 24
Prospectus supplement
4:00pm
service fees
Medical director fees
Department of Defense observational studies
Other revenues2
Total net revenue
Patient services fees include … Oaks related to the Company’s CyPath® Lung test, and (3) CyPath® Lung tests purchased by the U.S. Department of Defense (“DOD”) for an observational
8-K
EX-99.1
BIAF
BioAffinity Technologies Inc
15 May 24
Results of Operations and Financial Condition
6:07pm
.
Continued to advance new product development initiatives in collaboration with the U.S Department of Defense’s largest military health organization
424B3
BIAF
BioAffinity Technologies Inc
16 Apr 24
Prospectus supplement
7:19pm
and researcher is an important asset for bioAffinity Technologies.
Continuation of Department of Defense Research
In the fourth quarter of 2023, we … began selling CyPath® Lung tests to the Department of Defense (DOD) to conduct an observational study, “Detection of Abnormal Respiratory Cell
POS AM
p9i4wvtn74sxqk
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
8-K
EX-99.1
qlku u2xl
1 Apr 24
Results of Operations and Financial Condition
4:00pm
8-K
EX-10.1
b6oqe5zk203
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
424B5
kqc7d6ek173zn t31cr
8 Mar 24
Prospectus supplement for primary offering
12:18pm
424B5
wlc b95ue
7 Mar 24
Prospectus supplement for primary offering
9:57pm
424B5
ie3navmxu26
28 Nov 23
Prospectus supplement for primary offering
4:00pm
S-3
3qimighx3h86xw
16 Nov 23
Shelf registration
5:23pm
8-K
EX-99.1
rjquyy0h bh
15 Nov 23
Results of Operations and Financial Condition
5:07pm